A detailed history of Allspring Global Investments Holdings, LLC transactions in Insmed Inc stock. As of the latest transaction made, Allspring Global Investments Holdings, LLC holds 390,134 shares of INSM stock, worth $28.8 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
390,134
Previous 328,073 18.92%
Holding current value
$28.8 Million
Previous $22 Million 29.57%
% of portfolio
0.05%
Previous 0.04%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$62.0 - $79.01 $3.85 Million - $4.9 Million
62,061 Added 18.92%
390,134 $28.5 Million
Q2 2024

Jul 26, 2024

BUY
$22.0 - $69.71 $7.12 Million - $22.6 Million
323,772 Added 7527.83%
328,073 $22 Million
Q1 2024

Apr 18, 2024

SELL
$25.72 - $29.94 $182,560 - $212,514
-7,098 Reduced 62.27%
4,301 $116,000
Q4 2023

Jan 25, 2024

SELL
$23.42 - $31.74 $188,156 - $254,999
-8,034 Reduced 41.34%
11,399 $353,000
Q3 2023

Oct 27, 2023

BUY
$19.86 - $26.93 $385,939 - $523,330
19,433 New
19,433 $490,000
Q2 2023

Jul 18, 2023

BUY
$16.44 - $21.1 $31,137 - $39,963
1,894 Added 4.16%
47,470 $1 Million
Q1 2023

Apr 13, 2023

SELL
$16.26 - $21.73 $9,170 - $12,255
-564 Reduced 1.22%
45,576 $777,000
Q4 2022

Jan 23, 2023

BUY
$16.98 - $23.15 $108,807 - $148,345
6,408 Added 16.13%
46,140 $0
Q3 2022

Oct 26, 2022

SELL
$20.88 - $28.21 $5,512 - $7,447
-264 Reduced 0.66%
39,732 $855,000
Q2 2022

Jul 25, 2022

SELL
$17.07 - $25.71 $693,861 - $1.05 Million
-40,648 Reduced 50.4%
39,996 $788,000
Q1 2022

May 02, 2022

BUY
$20.42 - $28.13 $216,431 - $298,149
10,599 Added 15.13%
80,644 $1.9 Million
Q4 2021

Jan 28, 2022

BUY
$25.89 - $33.45 $1.81 Million - $2.34 Million
70,045 New
70,045 $1.91 Million

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $10B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Allspring Global Investments Holdings, LLC Portfolio

Follow Allspring Global Investments Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allspring Global Investments Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Allspring Global Investments Holdings, LLC with notifications on news.